An opportunity for us to consider working together just surfaced. A sponsor of ours is seeking our help to identify a test that could be used on site to increase the enrolment of patients suffering of NASH. Currently, the local community centers are not equipped or proficient in this disease area and would like to access a test that could be used as a pre-screen to enriched the target population.

Pappas Health has used the LIVERFASt test as a new addition to our practice, to provide further insight into our patients liver and overall health. We see it as an important addition to providing overall care and have been pleased with its performance and results so far

Liver disease is a silent killer with millions of Americans at potential risk. The strategy that Fibronostics is using to quickly assess a patient for the likelihood or existence of liver disease is badly needed. If their plan to reach the liver disease market with an effective and easily administered test is successful, they will make a significant contribution to the process of identification and treatment of liver disease.